In conclusion, these results underlined the proof of concept that this strategy combining NMD inhibitor and readthrough activities could be applied to CMT patients exhibited nonsense mutations in GDAP1, offering a restored, or a less severe, phenotype. This evidence concerns the gene PLA1A and Charcot-Marie-Tooth disease.